Table 1

Baseline characteristics of all spontaneous reports for antidiabetic drugs in the WHO VigiBase (1999–2009)

VariableSpontaneous reports (N = 305,415)
Patient age, mean (SD), years59.7 (14.3)
Age (missing)63,212 (20.7)
Female sex182,130 (59.6)
Sex (missing)9,100 (3.0)
Reporter
 Health care professional92,896 (30.4)
 Nonhealth care professional129,287 (42.3)
 Study/literature218 (0.1)
 Unknown45,308 (14.8)
 Other37,706 (12.3)
Reporting year
 1999–200493,255 (30.5)
 2005–2009212,160 (69.5)
Region
 Europe19,252 (6.3)
 United States273,079 (89.4)
 Other13,084 (4.3)
Antidiabetic drugs involved
 Monotherapy288,434 (94.4)
 Biguanides21,763 (7.1)
 Sulfonylurea derivative16,675 (5.5)
 Thiazolidinediones57,814 (18.9)
 Dipeptidyl peptidase-4 inhibitors8,083 (2.6)
 Insulin80,347 (26.3)
 Dual therapy14,057 (4.6)
 2 oral antidiabetics11,991 (3.9)
 Biguanide, sulfonylurea derivative2,413 (0.8)
 Biguanide, thiazolidinediones1,087 (0.4)
 Sulfonylurea derivatives, thiazolidinediones866 (0.3)
 Oral antidiabetic + insulin2,066 (0.7)
 Triple therapy2,924 (1.0)
Concomitant medication
 Antibiotics (J01)5,072 (1.7)
 Immunosuppressants (L04)2,013 (0.7)
 Corticosteroids for systemic use (H02)4,527 (1.5)
  • All data except patient age are shown as number (%).